Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Salud

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Anales De Medicina Interna (Madrid, Spain : 1984)|July 8, 2008
[Accuracy of pleural fluid cytology in malignant effusions]S Bielsa, M J Panadés, R Egido, et al.
Revista Espanola De Cardiologia|January 1, 1978
[Total thoracic ectopia cordis]A Salud Ariza, C Cintado Bueno, M Cañadas, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 27, 2015
Clinical guideline SEOM: hepatocellular carcinomaJ Sastre, R Díaz-Beveridge, J García-Foncillas, et al.
Lupus|May 4, 2004
Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromesR Solans-Laqué, C Pérez-Bocanegra, A Salud-Salvia, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 1, 2020
Breakthrough cancer pain: review and calls to action to improve its managementC Camps Herrero, N Batista, N Díaz Fernández, et al.
Cancer Treatment and Research Communications|July 13, 2019
Circulating tumor cells (CTCs) and cytokeratin 19 (CK19) mRNA as prognostic factors in heavily pretreated patients with metastatic breast cancerS Morales, A Velasco, A Gasol, et al.
British Journal of Cancer|November 3, 2005
Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancerJ Feliu, C Castañón, A Salud, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 16, 2011
Recommendations and expert opinion on the adjuvant treatment of colon cancer in SpainJ M Vieitez, R García-Carbonero, J Aparicio, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 25, 2021
Patient profiles as an aim to optimize selection in the second line setting: the role of afliberceptB González Astorga, F Salvà Ballabrera, E Aranda Aguilar, et al.
British Journal of Cancer|March 23, 2006
XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancerJ Feliu, A Salud, P Escudero, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Anales De Medicina Interna (Madrid, Spain : 1984)|July 8, 2008
[Accuracy of pleural fluid cytology in malignant effusions]S Bielsa, M J Panadés, R Egido, et al.
Revista Espanola De Cardiologia|January 1, 1978
[Total thoracic ectopia cordis]A Salud Ariza, C Cintado Bueno, M Cañadas, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 27, 2015
Clinical guideline SEOM: hepatocellular carcinomaJ Sastre, R Díaz-Beveridge, J García-Foncillas, et al.
Lupus|May 4, 2004
Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromesR Solans-Laqué, C Pérez-Bocanegra, A Salud-Salvia, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 1, 2020
Breakthrough cancer pain: review and calls to action to improve its managementC Camps Herrero, N Batista, N Díaz Fernández, et al.
Cancer Treatment and Research Communications|July 13, 2019
Circulating tumor cells (CTCs) and cytokeratin 19 (CK19) mRNA as prognostic factors in heavily pretreated patients with metastatic breast cancerS Morales, A Velasco, A Gasol, et al.
British Journal of Cancer|November 3, 2005
Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancerJ Feliu, C Castañón, A Salud, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 16, 2011
Recommendations and expert opinion on the adjuvant treatment of colon cancer in SpainJ M Vieitez, R García-Carbonero, J Aparicio, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 25, 2021
Patient profiles as an aim to optimize selection in the second line setting: the role of afliberceptB González Astorga, F Salvà Ballabrera, E Aranda Aguilar, et al.
British Journal of Cancer|March 23, 2006
XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancerJ Feliu, A Salud, P Escudero, et al.
Pageof 5